目的 观察盐酸氨基葡萄糖治疗膝骨关节炎（KOA）的临床疗效。 方法 2010年5月－2012年7月将130例经膝关节镜清理术后的KOA患者随机分成A、B两组，每组65例。A组联合口服盐酸氨基葡萄糖胶囊750 mg，2次/d，6周为1个疗程，治疗3个疗程；B组联合口服尼美舒利胶囊0.1 g，2次/d，服用12周。采用Lequesne指数作为疗效评定指标，观察治疗前后膝关节体征及症状变化，休息痛、运动痛、压痛、肿胀、晨僵和行走能力的改善情况。 结果 B组患者在治疗早期症状改善优于同期A组，且在第3个月有统计学意义（P＜0.05），随着治疗时间的延长，A组患者总有效率在1、3、6个月分别为70.8%、76.9%和92.3%，均呈逐渐上升趋势，且第6个月疗效较前2个时间点差异有统计学意义（P＜0.05）。分别停药后继续随访至1年，两组患者总有效率均有所下降，但A组疗效仍优于B组，且有统计学意义（P＜0.05）。A组出现不良反应2例，B组4例，均较轻微，无严重不良事件发生。 结论 盐酸氨基葡萄糖在改善OA患者膝关节症状等方面效果肯定，且疗效较稳定，安全性良好；但远期疗效仍需随访观察。
ObjectiveTo evaluate the therapeutic effect of glucosamine hydrochloride combined with Tenghuangjiangu tablets on knee osteoarthritis. MethodsFrom August 2012 to February 2014, 180 patients with knee osteoarthritis were randomly divided into three groups with 60 in each. Patients in group A were treated with glucosamine hydrochloride; patients in group B were treated with Tenghuangjiangu tablets; and patients in group C were treated with the combination of glucosamine hydrochloride and Tenghuangjiangu tablets. After the 12-week treatment, clinical efficacy and safety of the treatment were observed and compared with those before the treatment. ResultsThe twenty-meter walking pain, Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and the joint tenderness in the three groups 12 weeks after the treatment and 4 weeks after withdrawal improved obviously compared with those before the treatment (P<0.05), and the difference between the results of 12 weeks after treatment and 4 weeks after withdrawal was not significant (P>0.05). The improvement in group C was better than both group A and B with significant differences (P<0.05), while the difference between group A and B was not significant (P>0.05). There was no obvious abnormal routine blood and urine test result or damage of liver and lung functions during the treatment in all the three groups. Twelve weeks after treatment, six patients with abdominal ache were found in group A with an incidence of 10.0%; 5 abdominal ache and 2 diarrhea were in group B with a rate of 12.5%; and 4 abdominal ache and 3 diarrhea were in group C with a rate of 12.5%. All the patients completed the treatment. No significant difference in the incidence of adverse reactions was found among the three groups (P>0.05). ConclusionThe therapeutic effect of combined glucosamine hydrochloride and Tenghuangjiangu tablets is obvious on knee osteoarthritis with low incidence of adverse reactions.
目的 观察盐酸氨基葡萄糖胶囊在髌骨骨折内固定术后促进膝关节功能恢复及缓解患者疼痛等临床症状方面的疗效。 方法 选取2009年1月－2012年1月收治入院的髌骨横行骨折患者52例，采用随机数字表法将患者随机分为试验组以及对照组，其中试验组患者26例，对照组患者26例，两组患者的性别、年龄、病情等临床资料，差异无统计学意义（P＞0.05）,具有可比性。其中，对照组仅在术后进行康复锻炼，试验组术后给予盐酸氨基葡萄糖内服，连续服用3个月。根据术后2、6周，6、12个月随访记录中的膝关节功能评分（采用KSS评分）分析疗效。 结果 对照组和试验组在骨折愈合程度比较差异无统计学意义（P＞0.05），试验组的膝关节功能评分在早期与对照组差异无统计学意义（P＞0.05），但在第12个月的随访评分中，试验组患者膝关节功能评分较对照组差异具有统计学意义（P＜0.05）。 结论 盐酸氨基葡萄糖胶囊有利于髌骨骨折术后患者的功能恢复及疼痛症状的缓解。
目的 观察比较盐酸氨基葡萄糖单独使用及与硫酸软骨素联合使用治疗腰椎小关节骨关节炎（LFOA） 的临床疗效。 方法 2009年1月－2011年1月，将80例LFOA患者随机分成两组，A组口服盐酸氨基葡萄糖，B组口服盐酸氨基葡萄糖和硫酸软骨素两种药物，6周为1个疗程，间断治疗4个疗程。分别比较用药前与用药后3、6周及5、8、11个月时的日本骨科协会（JOA）评分、晨僵和压痛程度变化。 结果 治疗后，两组的JOA评分在各观察时点均增加，与治疗前比较差异有统计学意义（P＜0.05）。组间行JOA评分治疗改善率的比较，在各观察时点差异均有统计学意义（P＜0.05），B组JOA评分改善率优于A组。治疗3周后，两组晨僵和压痛评分均降低，与本组治疗前比较差异有统计学意义（P＜0.05）；组间比较，差异亦有统计学意义（P＜0.05），B组晨僵和压痛程度均低于A组。第6周，第5、8、11个月，两组组间比较晨僵和压痛程度差异均无统计学意义（P＞0.05），但各疗程结束后两组晨僵和压痛程度均呈持续降低趋势。 结论 单独应用盐酸氨基葡萄糖及盐酸氨基葡萄糖与硫酸软骨素的联合应用治疗LFOA疗效确切，联合用药优于单独应用盐酸氨基葡萄糖。
【Abstract】 Objective To evaluate the results of glucosamine hydrochloride in the treatment of knee degenerativeosteoarthritis (DOA) . Methods From February 2006 to January 2007, 60 patients with knee DOA were treated with glucosaminehydrochloride,including 15 males and 45 females. The ages of patients ranged from 41 to 67 years with an average ageof 57.5 years. The disease course ranged from 6 months to 3 years. Oral glucosamine hydrochloride was given twice a day, each750 mg, for a 6-week course of treatment; another course of treatment was repeated after 4 months. After two courses of treatment,the international standard DOA score of Lequesne index was used to evaluate the rest of knee pain, sports pain, tenderness,joints activity, morning stiffness and walking abil ity. Results All 60 patients finished treatment, various cl inical symptomsfor DOA disappeared completely in 31 cases and subsided in 27 cases; the cure rate was 51.7% and the total response rate was96.7%. The scores of rest pain, sport pain, tenderness, joints activity, morning stiffness and the abil ity to walk for knee after treatmentwere 0.5±0.2,0.7±0.4,0.8±0.3,0.9±0.4,0.6±0.3 and 0.9±0.4, showing statistically significant differences (P lt; 0.01) whencompared with preoperation (1.6±0.5,2.1±0.4,2.2±0.5,1.8±0.6,1.7±0.4 and 2.0±0.4). Adverse effect occurred in 3 cases (5%)and the patients recovered without special treatment. Conclusion Glucosamine hydrochloride can cure knee DOA withsymptom-rel ieving and joint function-improving action.
目的 观察评价盐酸氨基葡萄糖结合塞来昔布治疗膝骨关节炎（KOA）的疗效及安全性。 方法 2001年3月－2012年3月采用随机对照方法，将184例KOA患者随机分为对照组与试验组，各92例。对照组单独给予塞来昔布，试验组给予塞来昔布和盐酸氨基葡萄糖，共治疗8周，停药后继续观察4周。采用Lequesne指数作为疗效评分标准，观察服药前后的膝关节症状变化，包括休息痛、运动痛、压痛、肿胀、晨僵和行走能力的改善程度，纪录不良反应及实验室生化指标等。 结果 两组Lequesne指数在治疗前相比均明显下降，两组治疗8周后Lequesne总指数比较差异均有统计学意义（P＜0.05）。治疗8周后试验组总有效率明显优于对照组。安全性方面两组比较无差异。 结论 盐酸氨基葡萄糖结合塞来昔布治疗KOA，能明显改善患者的临床症状，疗效优于单纯的塞来昔布治疗，且不会增加药物不良反应，具有较好的临床价值。
ObjectiveTo explore the therapeutic effect of glucosamine hydrochloride combined with calcium and vitamin D on knee osteoarthritis. MethodsA total of 120 female outpatients with knee osteoarthritis from January 2014 to January 2015 were selected. The patients were randomly divided into study group and control group (60 patients in each group) according to their treatment sequence. The patients in the study group were given oral calcium citrate, alfacalcidol and glucosamine hydrochloride while those in the control group were given glucosamine hydrochloride only. Both groups were investigated and scored by Western Ontario and McMaster University Osteoarthritis Index (WOMAC) questionnaire before and three and six months after treatment. ResultsThree and six months after the treatment, WOMAC scores of both groups were lower than those before the treatment with significant differences (P<0.05). Three months after the treatment, WOMAC scores between the two groups didn't differ much (P>0.05), while the difference between the two groups was significant 6 months after the treatment (P<0.05). Three months after the treatment, the difference of total effective rate in the study group (43.3%) and control group (41.7%) was not significant (P>0.05), while the rate in the study group (65.0%) was obviously higher than that in the control group (46.7%) 6 months after the treatment (P<0.05). ConclusionGlucosamine hydrochloride has exact effect on knee osteoarthritis. There are differences in the therapeutic effect on knee osteoarthritis between glucosamine hydrochloride combined with calcium and vitamin D and glucosamine hydrochloride alone after six-month treatment.
ObjectiveTo discuss the effect of glucosamine-hydrochloride (Glu/Ch) in protecting and repairing the cartilage in blood-induced joint damage (BJD) in vivo. MethodsThirty-two adult New Zealand rabbits were randomly divided into 4 groups (n=8):high-dose Glu/Ch treated group (group A), low-dose Glu/Ch treated group (group B), positive control group (group C), and negative control group (group D). A joint bleeding model was established by blood injection into articular cavity in groups A, B, and C. Glu/Ch was given by gavage in groups A (250 mg/kg) and B (21.5 mg/kg) once a day for 8 weeks, and the same dosage of saline was given in groups C and D. The serum cartilage oligomeric matrix protein (COMP), serum chondroitin sulfate 846(CS846), and urinary C-terminal telopepide of type II collagen (CTX-II) were measured at 3 days, 7 days, 2 weeks, and 8 weeks after modeling. The expressions of cytokines such as interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) in synovial fluid were analyzed by ELISA at 8 weeks after modeling. The expression of matrix metalloproteinase 13(MMP-13) was detected by immunohistochemistry. Alcian blue staining and Safranin-O staining were performed to calculate the percentage of the positive staining areas. The proteoglycan content was detected by semi-quantitative analysis in the articular cartilage. ResultsThe COMP concentration was significantly higher in groups A, B, and C than group D, and in groups B and C than group A at 3 days after modeling (P<0.05); no significant difference was found among groups A, B, and D at 7 days (P>0.05), and it was significantly lower in groups A, B, and D than group C (P<0.05); there was no significant difference among 4 groups after 2 and 8 weeks (P>0.05). Difference in CS846 concentration had no significance among 4 groups at each time point (P>0.05). The CTX-II concentration of groups A, B, and C was significantly higher than that of group D at each time point (P<0.05); it was significantly lower in group A than groups B and C at 7 days, 2 weeks, and 8 weeks (P<0.05). The TNF-α concentration of groups A and B was significantly higher than group D, and was significantly lower than group C at 8 weeks (P<0.05), but no significant difference was observed between groups A and B (P>0.05). The IL-1β concentration was significantly higher in group C than the other groups (P<0.05), and in group B than groups A and D (P<0.05), but there was no significant difference between groups A and D (P>0.05). The MMP-13 expression was significantly higher in group C than groups A, B, and D (P<0.05), in groups A and B than group D (P<0.05). A significant decrease in the area stained with Alcian blue and Safranin-O was observed in group C. There were significant differences in the percentage of the positive stained areas of Alcian blue and Safranin-O among 4 groups (P<0.05). The relative quantities of proteoglycan from small to large in order was groups C, B, A, and D, respectively, showing significant differences (P<0.05). ConclusionThe metabolism disorder of cartilage matrix and synovium inflammatory reaction can be observed in rat joint bleeding model. Glu/Ch has certain protective effect on the cartilage after BJD by down-regulating IL-1β, TNF-α, and MMP-13, as well as increasing proteoglycan content in the cartilage.
ObjectiveTo investigate the therapeutic effect of glucosamine hydrochloride on chronic lumbago and backache. MethodsWe selected 328 outpatients with chronic lumbago and backache diagnosed between May 2014 and May 2015, and randomly (with single blind method) divided them into study group (n=172) and control group (n=156). Patients in the control group were treated with ibuprofen and placebo, while those in the study group were treated with ibuprofen and glucosamine hydrochloride. The short-form McGill pain questionnaire (SF-MPQ) was used for investigation at three time points (before the treatment, one month and two months after the treatment). ResultsThe score of SF-MPQ in the study group was 64.34±23.35 before the treatment, 44.04±13.22 one month after the treatment, and 19.87±8.11 two months after the treatment. While in the control group, the results at those three time points were 65.19±24.12, 47.04±11.36, and 54.44±21.39, respectively. There was no obvious difference between the two groups one month after the treatment (P>0.05). The pain was alleviated in both of the two groups one month after the treatment, while the therapeutic effect in the study group was significantly better than that in the control group two months after the treatment (P<0.05). Archenteric complications were found in 3 patients (1.74%) in the study group and 2 (1.28%) in the control group without a significant difference (P>0.05). ConclusionGlucosamine hydrochloride may effectively alleviate the lumbago and backache without any obvious adverse reactions.
ObjectiveTo investigate the clinical efficacy of glucosamine hydrochloride tablets in treating knee cartilage injury resulting from rheumatoid arthritis. MethodsWe selected 200 knee cartilage injury patients with rheumatoid arthritis treated in our hospital from January 2011 to January 2015 as the research subjects. They were divided into control group (n=98) and observation group (n=102) according to the time of admission. The control group was treated with conventional disease modifying anti-rheumatic drugs (DMARDs), while the observation group was treated with glucosamine hydrochloride tablets on the basis of DMARDs. The treatment effect was evaluated and compared between the two groups of patients 18, 36 and 54 weeks after the treatment. ResultsFifty-four weeks later, knee pain score of the observation group was better than that of the control group, and the difference was statistically significant (P ＜ 0.05) . The observation group had a lower Noyes evaluation level than the control group, and the difference was statistically significant (P ＜ 0.05) . Adverse reaction in the observation group was 3.92% and it was 3.06% in the control group, and the difference between the two groups was not statistically significant (P ＞ 0.05) . ConclusionGlucosamine hydrochloride tablets combined with conventional anti-rheumatic treatment is effective for knee cartilage injury caused by rheumatoid arthritis, which can promote cartilage repair, and it is worthy of clinical application.